Format

Send to

Choose Destination
Urol Clin North Am. 2003 Aug;30(3):623-31.

Monoclonal antibody-based therapy for renal cell carcinoma.

Author information

1
Nijmegen Center for Molecular Life Sciences, 190 Experimental Urology, University Medical Center Nijmegen, Geert Grooteplein Zuid 28, 6525 Nijmegen, The Netherlands. e.oosterwijk@uro.umcn.nl

Abstract

Monoclonal antibody G250 treatment may have a role in the management of metastatic RCC; however, particular subgroups who are more prone to benefit from this treatment must be delineated. High-risk patients may benefit from adjuvant treatment with this nontoxic treatment modality. Large cohort studies are needed to investigate this possibility.

PMID:
12953760
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center